Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
JERSEY CITY, N.J., April 06, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York City on Wednesday, April 13, 2016 at 12:10 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
